PUBLISHER: DelveInsight | PRODUCT CODE: 1226635
PUBLISHER: DelveInsight | PRODUCT CODE: 1226635
"CIMZIA Drug Insight and Market Forecast - 2032" report provides comprehensive insights about CIMZIA for Rheumatoid Arthritis in the 7MM. A detailed picture of the CIMZIA for Rheumatoid Arthritis in the 7MM, i.e., United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan for the study period 2019-2032 is provided in this report along with a detailed description of the CIMZIA for Rheumatoid Arthritis. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the CIMZIA market forecast, analysis for Rheumatoid Arthritis in the 7MM, descriptive analysis such as SWOT, analysts' views, comprehensive overview of market competitors, and brief about emerging therapies in Rheumatoid Arthritis.
CIMZIA (Certolizumab pegol) is a recombinant, humanized antibody Fab' fragment, with specificity for human tumor necrosis factor alpha (TNFα), conjugated to an approximately 40 kDa polyethylene glycol (PEG2MAL40K). The "Fab" fragment is manufactured in E. coli and subsequently subjected to purification and conjugation to PEG2MAL40K, to generate certolizumab pegol. The Fab' fragment is composed of a light chain with 214 amino acids and a heavy chain with 229 amino acids. The molecular weight of certolizumab pegol is approximately 91 kilo Daltons.
In Europe, UCB's biologic CIMZIA (certolizumab pegol), in combination with methotrexate (MTX), is indicated for the treatment of moderate to severe, active RA in adult patients when the response to disease-modifying antirheumatic drugs (DMARDs), including MTX, has been inadequate. CIMZIA can be given as monotherapy in cases of intolerance to MTX or when continued treatment with MTX is inappropriate. CIMZIA, in combination with MTX, is also indicated for the treatment of severe, active, and progressive RA in adults not previously treated with MTX or other DMARDs.
In March 2021, UCB announced that it had received its Declaration of Conformity (CE) mark for its first-in-class electromechanical injection device, ava Connect. The CE Mark indicates conformity with health, safety, and environmental protection standards for products sold within the European Economic Area (EEA). The ava Connect and its disposable dose-dispenser cartridge are used for self-injecting CIMZIA, and it is the first reusable device of its kind available for use with biologic treatment in rheumatology and dermatology in Europe.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
CIMZIA Analytical Perspective by DelveInsight
This report provides a detailed market assessment of CIMZIA in Rheumatoid Arthritis in the 7MM, i.e., United States, EU4 and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of CIMZIA for Rheumatoid Arthritis covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions